

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058244 A2

(51) International Patent Classification⁷: **A61K**
(21) International Application Number:
PCT/US2004/041788
(22) International Filing Date:
15 December 2004 (15.12.2004)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/529,517 15 December 2003 (15.12.2003) US
(71) Applicant (for all designated States except US): **ALEX-
ION PHARMACEUTICALS, INC.** [US/US]; 352 Knot-
ter Drive, Cheshire, CT 06410 (US).
(72) Inventors; and
(75) Inventors/Applicants (for US only): **BOWDISH,
Katherine, S.** [US/US]; 13754 Boquita Drive, Del Mar,
CA 92014 (US). **KRETZ-ROMMEL, Anke** [US/US];
4535 Kensington Drive, San Diego, CA 92116 (US).
(74) Agent: **FARBER, Mark**; Alexion Pharmaceuticals, Inc.,
352 Knotter Drive, Cheshire, CT 06410 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— without international search report and to be republished
upon receipt of that report


[Continued on next page]

(54) Title: NOVEL ANTI-DC-SIGN ANTIBODIES

A
IgG1 library



B
IgG2a library



(57) Abstract: Antibodies to DC-SIGN are disclosed which are capable of modulating the interaction of dendritic cells and T cells. In some embodiments, the antibodies inhibit the interaction of dendritic cells and T cells. In other embodiments, the antibodies are combined with peptides which are internalized in dendritic cells and presented to T cells, thereby generating an immune response to the peptide. The antibodies of the present disclosure may, in some embodiments, be useful in blocking viral binding, infection, and transmission.

BEST AVAILABLE COPY

WO 2005/058244 A2



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.